{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T12:58:13Z","timestamp":1792760293234,"version":"4.5.0"},"reference-count":33,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2018,6,1]]},"DOI":"10.1001\/jamadermatol.2018.0454","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T16:46:45Z","timestamp":1523465205000},"page":"670","source":"Crossref","is-referenced-by-count":101,"title":["Endocrine Therapy\u2013Induced Alopecia in Patients With Breast Cancer"],"prefix":"10.1001","volume":"154","author":[{"given":"Azael","family":"Freites-Martinez","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry","family":"Shapiro","sequence":"additional","affiliation":[{"name":"The Ronald O. Perelman Department of Dermatology, New York University School of Medicine, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Chan","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Fornier","sequence":"additional","affiliation":[{"name":"Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanu","family":"Modi","sequence":"additional","affiliation":[{"name":"Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devika","family":"Gajria","sequence":"additional","affiliation":[{"name":"Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Dusza","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shari","family":"Goldfarb","sequence":"additional","affiliation":[{"name":"Breast Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"doi180009r1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21387","article-title":"Cancer statistics, 2017.","volume":"67","author":"Siegel","year":"2017","journal-title":"CA Cancer J Clin"},{"key":"doi180009r2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.breast.2017.03.011","article-title":"Concurrent versus sequential adjuvant chemo-endocrine therapy in hormone-receptor positive early stage breast cancer patients: a systematic review and meta-analysis.","volume":"33","author":"Poggio","year":"2017","journal-title":"Breast"},{"issue":"24","key":"doi180009r4","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMra023246","article-title":"Aromatase inhibitors in breast cancer.","volume":"348","author":"Smith","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"doi180009r5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.5301\/tj.5000376","article-title":"Adjuvant aromatase inhibitor therapy in early breast cancer: what factors lead patients to discontinue treatment?","volume":"101","author":"Moscetti","year":"2015","journal-title":"Tumori"},{"issue":"10","key":"doi180009r6","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1634\/theoncologist.2013-0193","article-title":"Alopecia with endocrine therapies in patients with cancer.","volume":"18","author":"Saggar","year":"2013","journal-title":"Oncologist"},{"issue":"2","key":"doi180009r7","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1007\/s10549-013-2744-2","article-title":"Aromatase inhibitor therapy and hair loss among breast cancer survivors.","volume":"142","author":"Gallicchio","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"doi180009r8","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the common terminology criteria for adverse events version 4.0.","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"doi180009r9","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2006.12.029","article-title":"A new classification of pattern hair loss that is universal for men and women: basic and specific (BASP) classification.","volume":"57","author":"Lee","year":"2007","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"doi180009r10","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s001050051293","article-title":"Hairdex: a tool for evaluation of disease-specific quality of life in patients with hair diseases[in German].","volume":"52","author":"Fischer","year":"2001","journal-title":"Hautarzt"},{"issue":"1","key":"doi180009r11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.4103\/0974-7753.114700","article-title":"A randomized evaluator blinded study of effect of microneedling in androgenetic alopecia: a pilot study.","volume":"5","author":"Dhurat","year":"2013","journal-title":"Int J Trichology"},{"issue":"3","key":"doi180009r12","first-page":"418","article-title":"Selective estrogen receptor modulators: clinical spectrum.","volume":"20","author":"Cosman","year":"1999","journal-title":"Endocr Rev"},{"issue":"9793","key":"doi180009r13","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","article-title":"Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials.","volume":"378","author":"Davies","year":"2011","journal-title":"Lancet"},{"issue":"23","key":"doi180009r14","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","article-title":"American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer.","volume":"28","author":"Burstein","year":"2010","journal-title":"J Clin Oncol"},{"issue":"18","key":"doi180009r15","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study.","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"2","key":"doi180009r16","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.2001.19.2.343","article-title":"Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials.","volume":"19","author":"Klijn","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"doi180009r17","first-page":"1","article-title":"Molecular genetic and endocrine mechanisms of hair growth.","volume":"60","author":"Alonso","year":"2003","journal-title":"Horm Res"},{"issue":"8-9","key":"doi180009r18","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/S0531-5565(02)00093-1","article-title":"Molecular mechanisms of androgenetic alopecia.","volume":"37","author":"Tr\u00fceb","year":"2002","journal-title":"Exp Gerontol"},{"issue":"3","key":"doi180009r19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/j.1087-0024.2005.10102.x","article-title":"Prevalence of male and female pattern hair loss in Maryborough.","volume":"10","author":"Gan","year":"2005","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"6","key":"doi180009r20","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1093\/annonc\/mdt170","article-title":"Aromatase inhibitors induce \u2018male pattern hair loss\u2019 in women?","volume":"24","author":"Rossi","year":"2013","journal-title":"Ann Oncol"},{"issue":"2","key":"doi180009r21","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4103\/0974-7753.58555","article-title":"Dermoscopy in female androgenic alopecia: method standardization and diagnostic criteria.","volume":"1","author":"Rakowska","year":"2009","journal-title":"Int J Trichology"},{"issue":"6","key":"doi180009r22","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1096\/fj.07-099424","article-title":"Human hair follicles contain two forms of ATP-sensitive potassium channels, only one of which is sensitive to minoxidil.","volume":"22","author":"Shorter","year":"2008","journal-title":"FASEB J"},{"issue":"3 Pt 2","key":"doi180009r23","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0190-9622(87)70084-X","article-title":"Action of topical minoxidil in the bald stump-tailed macaque.","volume":"16","author":"Uno","year":"1987","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"doi180009r24","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.18632\/oncotarget.v5i8","article-title":"Minoxidil may suppress androgen receptor-related functions.","volume":"5","author":"Hsu","year":"2014","journal-title":"Oncotarget"},{"issue":"2","key":"doi180009r25","first-page":"73","article-title":"Comparison of the efficiency of anti-androgenic regimens consisting of spironolactone, Diane 35, and cyproterone acetate in hirsutism.","volume":"57","author":"Sert","year":"2003","journal-title":"Acta Med Okayama"},{"issue":"3","key":"doi180009r26","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1530\/eje.0.1500351","article-title":"A comparison between spironolactone and spironolactone plus finasteride in the treatment of hirsutism.","volume":"150","author":"Kelestimur","year":"2004","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"doi180009r27","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/BF02134038","article-title":"Endocrine and clinical effects of spironolactone in female hyperandrogenism.","volume":"240","author":"Siegberg","year":"1987","journal-title":"Arch Gynecol"},{"issue":"6","key":"doi180009r28","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1016\/j.canep.2013.10.004","article-title":"Spironolactone use and the risk of breast and gynecologic cancers.","volume":"37","author":"Biggar","year":"2013","journal-title":"Cancer Epidemiol"},{"issue":"5","key":"doi180009r29","first-page":"CD007628","article-title":"Interventions for female pattern hair loss.","author":"van Zuuren","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"doi180009r30","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1007\/s00520-009-0769-1","article-title":"Unanticipated toxicities from anticancer therapies: survivors\u2019 perspectives.","volume":"18","author":"Gandhi","year":"2010","journal-title":"Support Care Cancer"},{"issue":"7","key":"doi180009r31","first-page":"5","article-title":"Chemotherapy-induced hair loss.","volume":"15","author":"Tr\u00fceb","year":"2010","journal-title":"Skin Therapy Lett"},{"issue":"3","key":"doi180009r32","doi-asserted-by":"publisher","first-page":"e97","DOI":"10.1016\/j.jaad.2010.11.042","article-title":"Clinical severity does not reliably predict quality of life in women with alopecia areata, telogen effluvium, or androgenic alopecia.","volume":"66","author":"Reid","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"11","key":"doi180009r33","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/annonc\/mds095","article-title":"Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil\/epirubicin\/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients.","volume":"23","author":"Kluger","year":"2012","journal-title":"Ann Oncol"},{"key":"doi180009r3","first-page":"505","article-title":"Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET).","volume-title":"J Clin Oncol","author":"Pan","year":"2016"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2678038","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,6,13]],"date-time":"2018-06-13T16:56:37Z","timestamp":1528908997000},"score":1,"resource":{"primary":{"URL":"http:\/\/archderm.jamanetwork.com\/article.aspx?doi=10.1001\/jamadermatol.2018.0454"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,1]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018,6,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2018.0454","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6,1]]}}}